Most Recent
Shenzen-based radio manufacturer Hytera Communications has lost a bid to circumvent its discovery obligations in an ongoing patent dispute with Motorola, with a Federal Court judge rejecting its claims that supplying the documents could breach Chinese state secret and cybersecurity laws.
A group representing Australian winemakers has lost its objection to the European Commission's plan to register 'Avola' as a mark of geographical indication for wine.
The Commonwealth of Australia is weighing a bid to strike out Otsuka Pharmaceutical's defence as the government seeks lost subsidies after an almost seven-year long patent dispute over the antipsychotic drug, Abilify.
An education provider calling itself Trinity College Australia faces a lawsuit alleging it is duping consumers by trying to pass off as The University of Melbourne's famed residential college.
Australian coffee maker Vittoria Food & Beverage has won another challenge to a patent for a coffee pod system filed by a unit of Mondelez International.
Generic drug maker Alphapharm says rival Sanofi-Aventis waited to amend its injector pen patent until the heated IP battle between the two firms had commenced, despite knowing about the amendments for three years.
Generic Health has shaved two percent off the $25 million damages awarded pharmaceutical giant Bayer in a patent infringement case over Bayer's blockbuster oral contraceptive, Yasmin, but the discount is a far cry from the 15 percent it sought on appeal.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi's interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.
Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.
A group representing patent and trade mark lawyers is seeking to intervene in a high-stakes appeal over computer software patents.